AUSTIN, Texas, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that Greg B. Petersen has joined the Company’s Board of Directors to serve as an independent director, effective February 14, 2020. Greg will serve on the Audit and Compensation Committees. In addition, on January 31, 2020, Gregg Lapointe, submitted his resignation from the board of directors.

"We are happy that Greg Petersen has agreed to join our Board of Directors,” said Dr. Marc Hedrick, President and CEO of Plus Therapeutics. “Greg is a seasoned public company Chief Financial Officer and board member having served those positions for a number of high growth companies over his career. More specifically, Greg has extensive experience in both audit and compensation matters and will serve on both of these committees on our Board of Directors.”

About Plus Therapeutics, Inc.

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases.

Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers.

Our lead product candidate, DocePLUS, is a protein-stabilized PEGylated liposomal formulation of docetaxel, for which the process of preparation is patented. The active pharmaceutical ingredient, docetaxel, was approved by the U.S. FDA in 1999 and commonly used for treating cancers of the breast, head, neck, stomach, prostate, and lung.